| Varieties: | General Disease Prevention Medicine |
|---|---|
| Component: | Dabrafenib |
| Type: | The First Class |
| Pharmacodynamic Influential Factors: | Animal Species |
| Storage Method: | Normal |
| Product Name: | Dabrafenib |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Dabrafenib |
| CAS | 1195765-45-7 |
| Appearance | White crystalline powder |
| MF | C23H20F3N5O2S2 |
| MW | 519.561 |
| Purity | 99% |
| Shelf Life | 2 Years |
Dabrafenib is used alone or in combination with trametinib (Mekinist) to treat a certain types of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. It is also used along with trametinib to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected lymph nodes. Dabrafenib is also used in combination with trametinib to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body.
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.It is also used to treat a certain type of thyroid cancer that has spread to nearby tissues or to other parts of the body that has not responded to previous treatment(s). Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}